Omega-3 fatty acids for inflamed depression - A match/mismatch study.

Area of Science:

• Neuroscience
• Psychiatry
• Immunology

Background:

• Major Depressive Disorder (MDD) is heterogeneous, complicating treatment development.
• Inflammation, termed "inflamed depression," is a subtype potentially responsive to anti-inflammatory agents.
• Eicosapentaenoic acid (EPA), an omega-3 fatty acid, possesses anti-inflammatory properties and may benefit inflamed depression.

Purpose of the Study:

• To investigate if add-on EPA therapy demonstrates greater antidepressant efficacy in MDD patients with high baseline high-sensitivity C-reactive protein (hs-CRP) compared to those with low hs-CRP.
• To explore the potential of inflammation as a biomarker for predicting treatment response to EPA in MDD.

Main Methods:

• A randomized controlled trial involving 101 MDD patients receiving 8 weeks of add-on EPA (2.2g/day) plus standard antidepressant treatment.
• Patients were stratified into high (≥1 mg/L) and low hs-CRP groups, with outcomes assessed using the Hamilton Depression Rating Scale (HAMD-17).
• Intention-to-treat analysis was employed, with patients and raters blinded to hs-CRP status.

Main Results:

• MDD patients with hs-CRP ≥1 mg/L showed significantly greater improvement in HAMD-17 scores with EPA add-on therapy compared to those with lower hs-CRP.
• EPA treatment demonstrated a general antidepressant effect and specifically improved fatigue and sleep difficulties in the high hs-CRP group.
• A hs-CRP cut-off of ≥1 mg/L, but not ≥3 mg/L, was associated with superior antidepressant response to EPA.

Conclusions:

• Delineating MDD subgroups based on inflammation, indicated by hs-CRP levels, may be clinically relevant for predicting treatment response.
• Add-on EPA therapy shows potential as an effective intervention for MDD patients with elevated inflammation.
• This study supports the use of inflammation markers to personalize antidepressant treatment strategies.